Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors

Contributed by: Business Wire

Logo

Images

EP2_4 Receptor (Photo: Business Wire)

Tumor being attacked (Photo: Business Wire)

Business Wire embedded0

Tags

Biotechnology

Technology

Health

Pharmaceutical

Oncology

Health Technology

Research

Software

Artificial Intelligence

Science

Clinical Trials

clinical trial

More Like This

Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

Owkin Launches ATLANTIS: An Extensive Multimodal Patient Data Discovery Program Across 7 Countries in 11 Therapeutic Areas

K Navigator home screen.

Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

Owkin enters collaboration agreement with MSD to develop AI-powered diagnostics for cancer

PR Newswire associated0

J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI